AEI.Org: Outlook Outlooks List http://www.aei.org:80/outlook/100006?presentation=rss Sun, 22 Nov 2009 10:27:23 +0100 http://www.aei.org:80/views/images/accountRegistration/aeismall-reg.gif AEI http://www.aei.org:80/home 50 50 AEI Medicaid: The Forgotten Issue in Health Reform http://www.aei.org:80/outlook/100087 <html> <head> <title></title> </head> <body> Medicaid provides health care for the poorest and most severely disabled members of our society, and improving its quality should be a top priority. </body> </html> Tue, 30 Nov 1999 00:00:00 +0100 1999-11-30T00:00:00-0500 1999-11-30T00:00:00-0500 Private Health Plans: Where Is the Value? What Is the Point? http://www.aei.org:80/outlook/100083 <html> <head> <title></title> </head> <body> More attention should be paid to creating conditions under which competition can actually bring health care costs down--what is the point of private health plans otherwise? </body> </html> Tue, 30 Nov 1999 00:00:00 +0100 1999-11-30T00:00:00-0500 1999-11-30T00:00:00-0500 The Living Truth about "Death Panels" http://www.aei.org:80/outlook/100073 <html> <head> <title></title> </head> <body> The controversy over aspects of the House health care legislation that have been inappropriately equated with "death panels" has obscured the real problems with these provisions. </body> </html> Tue, 30 Nov 1999 00:00:00 +0100 1999-11-30T00:00:00-0500 1999-11-30T00:00:00-0500 The Politics and Principles of Health Care Reform http://www.aei.org:80/outlook/100070 <html> <head> <title></title> </head> <body> The health care system is ready for change, but to make it better, politicians should embrace five principles for designing effective, sustainable reform. </body> </html> Tue, 30 Nov 1999 00:00:00 +0100 1999-11-30T00:00:00-0500 1999-11-30T00:00:00-0500 Data Exclusivity for Biologics: What Is the Appropriate Period of Protection? http://www.aei.org:80/outlook/100068 <html> <head> <title></title> </head> <body> As Congress considers legislation that would allow imitative biological products, known as "biosimilars," to rely on the safety and efficacy data of original innovators, it must ensure that any provisions passed will foster, not stifle, discovery. </body> </html> Tue, 30 Nov 1999 00:00:00 +0100 1999-11-30T00:00:00-0500 1999-11-30T00:00:00-0500 Competitive Pricing for All Medicare Health Plans http://www.aei.org:80/outlook/100060 <html> <head> <title></title> </head> <body> Medicare should use competitive pricing to set the government contribution to the traditional fee-for-service Medicare plan and private Medicare Advantage plans. </body> </html> Tue, 30 Nov 1999 00:00:00 +0100 1999-11-30T00:00:00-0500 1999-11-30T00:00:00-0500 Life-Saving or Life-Threatening? http://www.aei.org:80/outlook/100049 <html> <head> <title></title> </head> <body> Ranbaxy's run-in with the FDA illustrates problems in developing-world drug production, but is there a place for less stringent quality standards? </body> </html> Tue, 30 Nov 1999 00:00:00 +0100 1999-11-30T00:00:00-0500 1999-11-30T00:00:00-0500 Taxing Health Insurance: A Tax Designed to Be Avoided http://www.aei.org:80/outlook/100046 <html> <head> <title></title> </head> <body> Capping the tax exclusion for employer-sponsored health insurance will bend the curve of health care costs and make it more feasible for smaller firms to offer more cost-effective insurance to their workers. </body> </html> Tue, 30 Nov 1999 00:00:00 +0100 1999-11-30T00:00:00-0500 1999-11-30T00:00:00-0500 Comparative Effectiveness Research: The Need for a Uniform Standard http://www.aei.org:80/outlook/100044 <html> <head> <title></title> </head> <body> If a new comparative effectiveness research agency is allowed to use different--or inferior--scientific standards than those imposed on the private sector, the government will be the only voice in CER. </body> </html> Tue, 30 Nov 1999 00:00:00 +0100 1999-11-30T00:00:00-0500 1999-11-30T00:00:00-0500 And Now, a Few Words about Antivirals for Pandemic Flu http://www.aei.org:80/outlook/100040 <html> <head> <title></title> </head> <body> The development of antivirals for pandemic flu provides important insights into the pharmaceutical industry's ability to advance public health. </body> </html> Tue, 30 Nov 1999 00:00:00 +0100 1999-11-30T00:00:00-0500 1999-11-30T00:00:00-0500